PerkinElmer Announces Agreement with Predictive Diagnostics That Allows for Comprehensive Biomarker Platform
PerkinElmer Inc., a leading provider of drug discovery, life science research, and analytical solutions and Predictive Diagnostics, Inc. (PDI), a leading clinical proteomics company and wholly owned subsidiary of Large Scale Biology Corporation, today announced they have entered into a collaborative partnership for advanced biomarker discovery technology to accelerate drug development and diagnostic testing.
Under the terms of the agreement, PerkinElmer will provide access to PDI’s proprietary Biomarker Amplification Filter (BAMF(TM)) Technology customized for PerkinElmer’s prOTOF(TM) 2000 MALDI O-TOF mass spectrometer to create the “industry standard” platform for biomarker discovery and analysis. PerkinElmer’s Life and Analytical Sciences sales and marketing team will exclusively offer PDI’s BAMF Technology services to leading pharmaceutical companies and major research institutions.
PDI’s BAMF(TM) Technology is a comprehensive suite of in silico machine learning technologies and advanced informatics tools that use a simple blood test for the discovery of biomarker fingerprints to diagnose diseases utilizing high-resolution mass spectrometry data. PDI has developed its BAMF Technology for use in serum-based tests for early diagnosis of cancer and other life-threatening diseases. “Predictive Diagnostics is a recognized leader in biomarker analysis software. Their proprietary set of algorithms and informatics capabilities will complement our mass spectrometry and proprietary consumables offerings and complete our total solution for biomarker discovery and screening.” said Peter Coggins, Ph.D., president of PerkinElmer Life and Analytical Sciences. “We believe this solution will be enabling technology for our pharmaceutical, biotech, and academic customers in the proteomic biomarker field.”
PerkinElmer’s prOTOF 2000 is part of the company’s High Content Proteomics solution, a comprehensive approach to proteomics research pioneered by PerkinElmer. Using advanced, innovative technologies, like the prOTOF(TM) 2000 MALDI O-TOF, PerkinElmer has developed a suite of tools that achieve maximum meaningful data from any sample, improving results and reproducibility. “PerkinElmer is the leader in state-of-the-art proteomic hardware and advanced purification solutions needed for advanced proteomic biomarker analysis,” said Kevin Ryan, CEO of Predictive Diagnostics. “We are confident that the combined strength of PerkinElmer’s proteomic hardware and PDI’s portfolio of discovery and diagnostic solutions will add significant value to our pharmaceutical and life sciences customers.”
Further details about PerkinElmer’s prOTOF(TM) 2000 mass spectrometer and its uses of BAMF Technology will be presented today by Dr. Gershon M. Wolfe and Dr. Guy della Cioppa of PDI at the Cambridge Healthtech Institute’s Protein Biomarker 2004 Conference in Philadelphia. For information on the conference or PerkinElmer’s proteomic offering please contact Dr. Mary Lopez of PerkinElmer 1-617-834-1862. (www.healthtech.com/2004/bmk/day2.asp ).
About PerkinElmer
PerkinElmer, Inc. is a global technology leader focused in the following businesses – Life and Analytical Sciences, Optoelectronics and Fluid Sciences. Combining operational excellence and technology expertise with an intimate understanding of our customers’ needs, PerkinElmer provides products and services in health sciences and other advanced technology markets that require innovation, precision and reliability. The Company serves customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
About Large Scale Biology Corporation
Large Scale Biology uses its biomanufacturing, functional genomics and proteomics technologies to develop and manufacture drugs, vaccines and diagnostics for effective treatment of disease. Corporate offices, Predictive Diagnostics, Inc. (www.predictivediagnostics.com), and Biopharmaceutical Development laboratories are headquartered in Vacaville, California, and the Company’s commercial-scale biomanufacturing facility is located in Owensboro, Kentucky. For more information about Large Scale Biology Corporation, visit the Company’s website at www.lsbc.com .
LSBC(R) and BAMF(TM) are trademarks of Large Scale Biology Corporation. prOTOF is a trademark of MDS Sciex. All other trademarks are the property of PerkinElmer, Inc.
